Immunology

Driven by Our Patients

Congress Materials

PNS 2023 | 17–20 June 2023 | View Materials
EAACI 2023 | 09–11 June 2023 | View Materials
ESID 2022 | 12–15 October 2022 | View Materials
ESID 2020 | 14–17 October 2020 | View Materials

Meet Us at an Event

IPIC 2023

8–10 November 2023

Rotterdam, The Netherlands

Details

Prescribing information for HAEGARDA^® and Berinert^® may vary depending on local approval in each country. Therefore, before prescribing HAEGARDA^® or Berinert^®, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics (SmPC) in your country.

HAEGARDA^® and Berinert^® are not available in all countries. Consult the CSL Behring Global Products List to see if HAEGARDA^® and Berinert^® are available in your country.

CSL Ltd Annual Report 2022. CSL Ltd. Published 2022. Accessed September 6, 2022. https://investors.csl.com/annualreport/2022/2/

CMD-BRN-0052
May 2023